全球基因生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球基因生物標記市場預計將從2025年的60.8億美元成長至2034年的144.7億美元，2026年至2034年的複合年成長率（CAGR）為10.11%。這一市場擴張的驅動力在於基因生物標記在疾病診斷、治療方案選擇和療效評估中日益重要的角色。基因生物標記包括遺傳變異、突變、基因表現模式和其他分子特徵，這些特徵能夠提供有關疾病生物學特徵的資訊。它們在腫瘤學領域尤其重要，因為生物標記檢測可以識別可能受益於標靶治療的患者。精準醫療的日益普及、分子診斷技術的進步以及利用生物標記的臨床試驗的擴展，都支撐著市場需求。製藥公司也正在利用基因生物標記來改進臨床研究並評估治療的潛在療效。

市場成長的驅動力來自次世代定序的進步、分子分析成本的降低、藥物研發投入的增加。診斷實驗室正在提升其識別臨床相關基因突變的能力，而製藥公司則將生物標記策略納入臨床試驗。基於特定生物標記的療法獲得監管部門批准以及伴隨診斷的開發進一步推動了市場擴張。生物資訊平台的改進使研究人員能夠更輕鬆地分析大規模基因組資料集，並識別分子特性與治療結果之間的相關性。此外，生物技術公司、學術機構和醫療服務提供者之間的合作正在加速新物標誌物的發現和檢驗。

該市場的未來前景取決於生物標記的持續發現、臨床檢驗的加強以及與常規醫療保健的更廣泛整合。液態生物檢體、多體學分析和人工智慧的進步可能有助於研究人員識別更多生物標記並監測疾病中的生物學變化。隨著支持性證據的積累，基於生物標記的療法可能會擴展到其他治療領域，包括腫瘤學。然而，數據解讀、檢測標準化、保險報銷以及特定基因組觀察的臨床意義等方面的挑戰依然十分嚴峻。持續投資於檢驗的檢測方法，並努力將生物標記結果納入臨床決策，將有助於加強基因生物標記在個人化醫療中的作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球基因生物標記市場：依適應症分類

• 市場分析、洞察與預測
• 癌症
• 心血管疾病
• 神經病變
• 腎臟疾病
• 自體免疫/發炎性疾病
• 其他

第5章 全球基因生物標記市場：依最終用戶分類

• 市場分析、洞察與預測
• 診斷檢查室
• 醫院
• 製藥和生物技術公司
• 其他

第6章 全球基因生物標記市場：依技術平台分類

• 市場分析、洞察與預測
• 次世代定序
• PCR
• 微陣列
• 其他

第7章 全球基因生物標記市場：依生物標記類型分類

• 市場分析、洞察與預測
• 預測性生物標記
• 預後生物標記

第8章 全球基因生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Foundation Medicine/Roche
  • Guardant Health
  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Natera
  • Tempus AI
  • Exact Sciences/Abbott
  • NeoGenomics
  • Caris Life Sciences
  • Personalis
  • Fulgent Genetics
  • Invitae
  • Labcorp
  • Quest Diagnostics
  • Veracyte
  • Burning Rock Biotech
  • BGI Genomics
  • GeneCentric Therapeutics
  • Bio-Rad Laboratories

The global genomic biomarkers market size is expected to reach USD 14.47 Billion in 2034 from USD 6.08 Billion in 2025, growing at a CAGR of 10.11% during 2026-2034.This market is growing as genomic biomarkers become increasingly important in disease diagnosis, treatment selection, and the assessment of therapeutic response. Genomic biomarkers include genetic variations, mutations, gene expression patterns, and other molecular characteristics that provide information about disease biology. Their use is particularly significant in oncology, where biomarker testing can help identify patients who may benefit from targeted therapies. Increasing interest in precision medicine, improvements in molecular diagnostic technologies, and the expansion of biomarker-driven clinical trials are supporting demand. Pharmaceutical developers are also using genomic biomarkers to refine clinical research and evaluate potential treatment effectiveness.

Market growth is driven by advances in next-generation sequencing, declining costs of molecular analysis, and increasing investment in drug development. Diagnostic laboratories are expanding their capabilities to identify clinically relevant genetic alterations, while pharmaceutical companies are incorporating biomarker strategies into clinical trials. Regulatory recognition of certain biomarker-guided treatments and the development of companion diagnostics are further supporting market expansion. Improved bioinformatics platforms are helping researchers analyze large genomic datasets and identify associations between molecular characteristics and treatment outcomes. In addition, collaborations between biotechnology companies, academic institutions, and healthcare providers are encouraging the discovery and validation of new biomarkers.

The future prospects of this market will depend on continued biomarker discovery, stronger clinical validation, and broader integration into routine healthcare. Advances in liquid biopsy, multi-omics analysis, and artificial intelligence may help researchers identify additional biomarkers and monitor changes in disease biology. Biomarker-guided treatment selection could expand across oncology and other therapeutic areas as supporting evidence develops. However, challenges involving data interpretation, test standardization, reimbursement, and the clinical significance of certain genomic findings will remain important. Continued investment in validated testing methods and the integration of biomarker results into clinical decision-making could strengthen the role of genomic biomarkers in personalized healthcare.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Renal Disorders
• Auto-Immune & Inflammatory Diseases
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Others

By Technology Platform

• Next-Generation Sequencing
• PCR
• Microarray
• Others

By Biomarker Type

• Predictive Biomarkers
• Prognostic Biomarkers

COMPANIES PROFILED

• Foundation Medicine/Roche, Guardant Health, Illumina, Thermo Fisher Scientific, QIAGEN, Natera, Tempus AI, Exact Sciences/Abbott, NeoGenomics, Caris Life Sciences, Personalis, Fulgent Genetics, Invitae, Labcorp, Quest Diagnostics, Veracyte, Burning Rock Biotech, BGI Genomics, GeneCentric Therapeutics, Bio-Rad Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOMIC BIOMARKERS MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Renal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Auto-Immune & Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOMIC BIOMARKERS MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOMIC BIOMARKERS MARKET: BY TECHNOLOGY PLATFORM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology Platform
• 6.2. Next-Generation Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Microarray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOMIC BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Biomarker Type
• 7.2. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Prognostic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENOMIC BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By End User
  • 8.2.3 By Technology Platform
  • 8.2.4 By Biomarker Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By End User
  • 8.3.3 By Technology Platform
  • 8.3.4 By Biomarker Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By End User
  • 8.4.3 By Technology Platform
  • 8.4.4 By Biomarker Type
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By End User
  • 8.5.3 By Technology Platform
  • 8.5.4 By Biomarker Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By End User
  • 8.6.3 By Technology Platform
  • 8.6.4 By Biomarker Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENOMIC BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Foundation Medicine/Roche
  • 10.2.2 Guardant Health
  • 10.2.3 Illumina
  • 10.2.4 Thermo Fisher Scientific
  • 10.2.5 QIAGEN
  • 10.2.6 Natera
  • 10.2.7 Tempus AI
  • 10.2.8 Exact Sciences/Abbott
  • 10.2.9 NeoGenomics
  • 10.2.10 Caris Life Sciences
  • 10.2.11 Personalis
  • 10.2.12 Fulgent Genetics
  • 10.2.13 Invitae
  • 10.2.14 Labcorp
  • 10.2.15 Quest Diagnostics
  • 10.2.16 Veracyte
  • 10.2.17 Burning Rock Biotech
  • 10.2.18 BGI Genomics
  • 10.2.19 GeneCentric Therapeutics
  • 10.2.20 Bio-Rad Laboratories